Literature DB >> 26372436

Biological therapy and dentistry: a review paper.

Lida Radfar1, Roshanak E Ahmadabadi2, Farah Masood2, R Hal Scofield3.   

Abstract

In recent years, a new class of drugs has revolutionized the treatment of autoimmune, allergic, infectious, and many more diseases. This new class of drugs is made of 3 groups-cytokines, monoclonal antibodies, and fusion proteins-that may target special damaged cells but not all the cells. These drugs may have side effects such as infection, hypersensitivity, hematologic disorders, cancer, hepatotoxicity, and neurologic disorders. However, there is not enough evidence or long-term studies of the mechanism of action and side effects of these drugs. Patients receiving biological therapies may need special consideration in dentistry. This paper is a review of the classification, mechanism of action, and side effects of these drugs and dental consideration for patients receiving biological therapies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26372436      PMCID: PMC5206793          DOI: 10.1016/j.oooo.2015.07.032

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  21 in total

Review 1.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 2.  Overview of monoclonal antibodies in cancer therapy: present and promise.

Authors:  M Stern; R Herrmann
Journal:  Crit Rev Oncol Hematol       Date:  2005-04       Impact factor: 6.312

3.  British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

Authors:  C H Smith; A V Anstey; J N W N Barker; A D Burden; R J G Chalmers; D A Chandler; A Y Finlay; C E M Griffiths; K Jackson; N J McHugh; K E McKenna; N J Reynolds; A D Ormerod
Journal:  Br J Dermatol       Date:  2009-11       Impact factor: 9.302

Review 4.  Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.

Authors:  Michael Campoli; Robert Ferris; Soldano Ferrone; Xinhui Wang
Journal:  Clin Cancer Res       Date:  2009-12-22       Impact factor: 12.531

5.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012.

Authors:  Daniel E Furst; Edward Clark Keystone; Alexander K So; Jürgen Braun; Ferry C Breedveld; Gerd R Burmester; Fabrizio De Benedetti; Thomas Dörner; Paul Emery; Roy Fleischmann; Allan Gibofsky; J R Kalden; Arthur Kavanaugh; Bruce Kirkham; Philip Mease; A Rubbert-Roth; Joachim Sieper; Nora G Singer; Josef S Smolen; Piet L C M Van Riel; Michael H Weisman; Kevin L Winthrop
Journal:  Ann Rheum Dis       Date:  2013-04       Impact factor: 19.103

Review 6.  Anti-TNF therapy: safety aspects of taking the risk.

Authors:  Hemda Rosenblum; Howard Amital
Journal:  Autoimmun Rev       Date:  2011-05-05       Impact factor: 9.754

Review 7.  Adverse reactions to biologic agents: focus on autoimmune disease therapies.

Authors:  Susan J Lee; Arthur Kavanaugh
Journal:  J Allergy Clin Immunol       Date:  2005-10       Impact factor: 10.793

8.  Tumor necrosis factor inhibition and invasive fungal infections.

Authors:  Scott G Filler; Michael R Yeaman; Donald C Sheppard
Journal:  Clin Infect Dis       Date:  2005-08-01       Impact factor: 9.079

Review 9.  Immunosuppressants.

Authors:  Marian Fireman; Andrea F DiMartini; Scott C Armstrong; Kelly L Cozza
Journal:  Psychosomatics       Date:  2004 Jul-Aug       Impact factor: 2.386

Review 10.  The spectrum and types of adverse side effects to biological immune modulators: a proposal for new classification.

Authors:  M Zemková; L Jebavý; J Kotlárová; J Vlcek; R H Meyboom
Journal:  Folia Biol (Praha)       Date:  2007       Impact factor: 0.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.